|OBSEVA SA filed this Form 6-K on 03/30/2018|
Conclusions: Nolasiban has the potential to increase clinical pregnancy rate w/o increasing multiple pregnancy rate Nolasiban significantly increased ongoing pregnancy rate at 10 weeks: Pooled D3/D5 (primary): Placebo 28.5%, Nolasiban 35.6%, p=0.03 (7.1% absolute increase, 25% relative increase). The largest increase in ongoing pregnancy rate was seen with D5 ET, Placebo 34.7%, Nolasiban 45.9%, p=0.03 (11.2% absolute increase, 32% relative increase). Nolasiban very well tolerated with a safety profile not different from placebo. Potential of nolasiban primarily as an agent to increase IVF efficacy, but also to increase the safety of IVF by supporting SET, hence dramatically reducing multiple pregnancies (from 25 -40% to â^ 5%). As Standard of Care increasingly moves to D5 ET, US IMPLANT3 trial will focus on D5 ET.